T-Lymphocytes, Cytotoxic
"T-Lymphocytes, Cytotoxic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Descriptor ID |
D013602
|
MeSH Number(s) |
A11.118.637.555.283.875 A11.118.637.555.567.550.500.200 A11.118.637.555.567.569.220.200 A11.118.637.555.567.569.500.200 A15.145.229.637.555.283.875 A15.145.229.637.555.567.550.500.200 A15.145.229.637.555.567.569.220.200 A15.145.229.637.555.567.569.500.200 A15.382.490.555.283.875 A15.382.490.555.567.550.500.200 A15.382.490.555.567.569.220.200 A15.382.490.555.567.569.500.200
|
Concept/Terms |
T-Lymphocytes, Cytotoxic- T-Lymphocytes, Cytotoxic
- Cytotoxic T-Lymphocyte
- T Lymphocytes, Cytotoxic
- T-Lymphocyte, Cytotoxic
- Cell-Mediated Lympholytic Cells
- Cell Mediated Lympholytic Cells
- Cell, Cell-Mediated Lympholytic
- Cell-Mediated Lympholytic Cell
- Cells, Cell-Mediated Lympholytic
- Lympholytic Cell, Cell-Mediated
- Lympholytic Cells, Cell-Mediated
- Cytotoxic T-Lymphocytes
- Cytotoxic T Lymphocytes
TC2 Cells- TC2 Cells
- Cell, TC2
- Cells, TC2
- TC2 Cell
TC1 Cells- TC1 Cells
- Cell, TC1
- Cells, TC1
- TC1 Cell
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Cytotoxic".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.283.875]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.550.500.200]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD8-Positive T-Lymphocytes [A11.118.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.500.200]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.283.875]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.550.500.200]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD8-Positive T-Lymphocytes [A15.145.229.637.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.500.200]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.283.875]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.550.500.200]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD8-Positive T-Lymphocytes [A15.382.490.555.567.569.220]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.220.200]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.500.200]
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Cytotoxic".
This graph shows the total number of publications written about "T-Lymphocytes, Cytotoxic" by people in this website by year, and whether "T-Lymphocytes, Cytotoxic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 | 2001 | 0 | 1 | 1 | 2002 | 1 | 4 | 5 | 2003 | 2 | 2 | 4 | 2004 | 4 | 1 | 5 | 2005 | 2 | 0 | 2 | 2006 | 4 | 1 | 5 | 2007 | 1 | 1 | 2 | 2008 | 1 | 1 | 2 | 2009 | 4 | 1 | 5 | 2010 | 6 | 0 | 6 | 2011 | 3 | 1 | 4 | 2012 | 3 | 0 | 3 | 2013 | 4 | 0 | 4 | 2014 | 4 | 0 | 4 | 2015 | 2 | 0 | 2 | 2016 | 2 | 0 | 2 | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes, Cytotoxic" by people in Profiles.
-
McLaughlin LP, Gottschalk S, Rooney CM, Bollard CM. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265.
-
St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 2016 08; 18(8):995-1001.
-
Spielmann G, Bollard CM, Kunz H, Hanley PJ, Simpson RJ. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy. Sci Rep. 2016 05 16; 6:25852.
-
Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis. 2015 Jul 15; 212(2):258-63.
-
LaVoy EC, Bollard CM, Hanley PJ, Blaney JW, O'Connor DP, Bosch JA, Simpson RJ. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exerc Immunol Rev. 2015; 21:144-53.
-
Bollard CM, Barrett AJ. Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):565-9.
-
Lam S, Sung J, Cruz C, Castillo-Caro P, Ngo M, Garrido C, Kuruc J, Archin N, Rooney C, Margolis D, Bollard C. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther. 2015 Feb; 23(2):387-95.
-
Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
-
Bollard CM, Heslop HE, Rooney CM. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1.
-
Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|